help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SHIRTCLIFFE, P. M.
Right arrow Articles by BEASLEY, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SHIRTCLIFFE, P. M.
Right arrow Articles by BEASLEY, R.

Am. J. Respir. Crit. Care Med., Volume 163, Number 6, May 2001, 1410-1414

The Effect of Delipidated Deglycolipidated (DDMV) and Heat-killed Mycobacterium vaccae in Asthma

PHILIPPA M. SHIRTCLIFFE, STEPHANIE E. EASTHOPE, SOO CHENG, MARK WEATHERALL, PAUL L. J. TAN, GRAHAM LE GROS, and RICHARD BEASLEY

Wellington Asthma Research Group, Department of Medicine, Wellington School of Medicine, Wellington South, New Zealand; Malaghan Institute of Medical Research, Wellington South, New Zealand; and Genesis Research and Development Corporation Limited, Auckland, New Zealand

Experimental and epidemiological evidence supports the hypothesis that exposure to mycobacteria has the potential to suppress the development of asthma and/or atopy and there are reports in the Chinese medical literature of repeated vaccination with inactivated BCG being effective in the management of asthma. Forty-three patients with stable moderately severe asthma who were skin prick test positive to house dust mite were randomized to receive two intradermal injections of either phosphate-buffered saline (placebo), heat-killed Mycobacterium vaccae (0.5 mg), or delipidated deglycolipidated Mycobacterium vaccae (DDMV) (0.05 mg). Markers of asthma severity were measured for 3 mo and blood eosinophil, IgE levels, and the T cell proliferative and cytokine responses were monitored. There were no significant differences between either treatment group and the placebo group for any of the outcome variables. There was also no difference between the treatment groups and placebo for eosinophil, IgE levels, or the T cell proliferative and cytokine response. The results indicate no effect of low dose intradermal DDMV or M. vaccae on asthma severity in patients with established asthma.




This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
C Gruber
Childhood immunisations and the development of atopic disease
Arch. Dis. Child., June 1, 2005; 90(6): 553 - 555.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
L. Camporota, A. Corkhill, H. Long, J. Lordan, L. Stanciu, N. Tuckwell, A. Cross, J.L. Stanford, G.A.W. Rook, S.T. Holgate, et al.
The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma
Eur. Respir. J., February 1, 2003; 21(2): 287 - 293.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. P. Cavallo, M. Elia, D. Giordano, C. Baldi, and R. Cammarota
Decrease of Specific and Total IgE Levels in Allergic Patients After BCG Vaccination: Preliminary Report
Arch Otolaryngol Head Neck Surg, September 1, 2002; 128(9): 1058 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 598 - 618.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society 		  ATS State of the Art 2009